Alzheimer’s
Roche signs Alzheimer’s deal with reMYND
September 7, 2010Research and Development Alzheimer's, Parkinson's, Roche, reMYND
Roche has signed a deal with Belgian biotech reMYND to develop new treatments for patients with Alzheimer’s and Parkinson’s disease. …
Lilly abandons late stage Alzheimer’s drug
August 17, 2010Research and Development Alzheimer's, lilly
Lilly is to abandon an Alzheimer’s drug in phase III development after results suggested it actually accelerated the disease rather …
Merck signs Alzheimer’s deal with Alectos
August 16, 2010Research and Development, Sales and Marketing Alzheimer's, Alzheimers, Merck & Co
Merck has entered a $289 million agreement with Canadian company Alectos Therapeutics in a bid to find new Alzheimer’s drugs. …
Pharma pools trial data for brain disorder research
June 14, 2010Research and Development Alzheimer's, Huntington's, Parkinson's, clinical trials, partnerships
Leading pharma companies have come together for a major new research collaboration aimed at improving clinical trials for Alzheimer’s, Parkinson’s, …
Baxter Alzheimer’s candidate shows promise
March 20, 2010Research and Development Alzheimer's, baxter
Baxter’s Gammagard has shown promise in treating Alzheimer’s disease, with patients showing better cognitive function and less brain enlargement than …
Pfizer suffers Alzheimer’s setback
March 4, 2010Research and Development Alzheimer's, Medivation, Pfizer
Pfizer has suffered a big setback with the oral Alzheimer’s disease treatment it is developing with biotech outfit Medivation. Investigational …
Government ups the ante in dementia research
February 26, 2010Research and Development Alzheimer's, dementia
The government has attempted to ‘up the ante’ in dementia research by convening a ministerial group comprising charities, scientists, research …
Boost for dementia research
November 9, 2009Alzheimer's, dementia
More funding will be made available for dementia research as a new ministerial group is created to champion the issue, …
AstraZeneca’s AZD3480 progresses in ADHD
July 11, 2009Sales and Marketing ADHD, Alzheimer's, Alzheimer's ADHD, AstraZeneca
AstraZeneca is to progress its AZD3480 (TC-1734) for attention deficit/hyperactivity disorder (ADHD) and has agreed to make a $10 million …
NICE defies pressure and keeps restrictions on Alzheimer’s
June 15, 2009Research and Development Alzheimer's, NICE
Patients with early stage Alzheimer's disease will still be denied access to drug treatment after NICE decided to retain its …
Alzheimer’s companies hope renewed by House of Lords
October 30, 2008Sales and Marketing Alzheimer's, NICE
The companies behind Alzheimer's drug Aricept have won the right to see the economic model NICE used to assess the …
Pfizer to co-market new Alzheimer’s drug
September 5, 2008Sales and Marketing Alzheimer's, Pfizer
Pfizer is to partner with American firm Medivation to develop and market a new drug for Alzheimer’s and Huntington’s disease.The …
Latest news from Datamonitor
September 4, 2008Research and Development Alzheimer's
Attention shifts from beta-amyloid to tau in the hunt for an Alzheimer's disease therapyIn years to come, scientists and pharmaceutical …
Eisai gets go ahead for Alzheimer’s appeal
December 10, 2007Alzheimer's, Eisai, NICE
Eisai is to make one more legal challenge to NICE by taking its case on Alzheimer’s drugs to the Court …
Eisai to appeal against Alzheimer’s court ruling
October 3, 2007Alzheimer's, Eisai, NICE
Eisai and Pfizer are to try once again to reverse NICE restrictions on Alzheimer’s drugs by appealing against the recent …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
